Collaboration Revenue (Tables)

3 Months Ended

Mar. 31, 2022

Research and Development [Abstract]

Schedule of Disaggregation of Revenue

The following table summarizes grant revenue for the periods presented (in millions):

	Three Months Ended March 31,
	2022		2021
BARDA	$	122	$	192
Other grant revenue	4		2
Total grant revenue	$	126	$	194

The following table summarizes our total consolidated revenue from our strategic collaborators for the periods presented (in millions):

	Three Months Ended March 31,
Collaboration Revenue by Strategic Collaborator:	2022		2021
Merck	$	10	$	—
Vertex	4		9
Other	1		1
Total collaboration revenue	$	15	$	10

Schedule of Changes in Balances of Receivables and Contract Liabilities

The following table presents changes in the balances of our receivables and contract liabilities related to our strategic collaboration agreements during the three months ended March 31, 2022 (in millions):

	December 31, 2021		Additions		Deductions		March 31, 2022
Contract Assets:
Accounts receivable	$	9	$	3	$	(9)	$	3
Contract Liabilities:
Deferred revenue	$	204	$	3	$	(15)	$	192

The following table summarizes the activities in deferred revenue for the three months ended March 31, 2022 (in millions):

	December 31, 2021		Additions		Deductions		March 31, 2022
Product sales	$	6,658	$	1,755	$	(2,548)	$	5,865
Grant revenue	6		—		—		6
Collaboration revenue	204		3		(15)		192
Total deferred revenue	$	6,868	$	1,758	$	(2,563)	$	6,063